Breaking News: AHB-137 Shows Promise in Chronic Hepatitis B Treatment
In a recent development that has the medical community buzzing, AusperBio Therapeutics has unveiled exciting late-breaking data from its Phase II trials of AHB-137, a novel treatment for chronic hepatitis B (CHB). But here's where it gets controversial: the results suggest a potential functional cure for this debilitating disease.
The data, presented at the prestigious AASLD 2025 conference, showcases a remarkable 48-week journey of two Phase II studies involving HBeAg-negative CHB patients on nucleos(t)ide analog (NA) therapy. The treatment, AHB-137, a unique unconjugated antisense oligonucleotide (ASO), has demonstrated robust and sustained antiviral responses, even 24 weeks after the end of treatment.
Imagine a scenario where patients with CHB, a condition that affects millions worldwide, could achieve complete or partial response, with HBsAg and HBV DNA levels dropping significantly. This is exactly what AHB-137 seems to offer, with the 300 mg, 24-week regimen showing the most promising results. And this is the part most people miss: the treatment was well-tolerated, with no new safety concerns arising during the off-treatment phase.
The presentation, titled "High Proportion of Participants Achieved Sustained Complete Response 24 Weeks After End of AHB-137 Treatment in HBeAg Negative Chronic Hepatitis B Participants on NA Therapy: Pooled Analysis of Two Phase 2 Studies in China," provides a detailed look at the potential of this innovative therapy. With a publication number of 5022, the study was presented on November 8, 2025, at the AASLD website, offering a comprehensive scientific program and abstracts for further exploration.
AHB-137, developed using AusperBio's cutting-edge Med-Oligo™ ASO technology platform, has already made waves in the medical community. Its promising preclinical and clinical results have been showcased at major international conferences, including EASL and AASLD. This dual-mechanism ASO has completed a global Phase I study and is now being extensively evaluated in multiple Phase II studies and a phase III trial in China. Supported by a global development strategy, AHB-137 is a step closer to its goal of offering a functional cure for HBV infection.
AusperBio, a clinical-stage biopharmaceutical company with a focus on oligonucleotide and targeted delivery technologies, is dedicated to transforming the treatment landscape for chronic hepatitis B. Their proprietary Med-OligoTM ASO platform has shown significant enhancements to current ASO therapeutics, opening doors to treat a wide range of diseases, from viral infections to genetic disorders.
As we delve deeper into the potential of AHB-137, one question remains: Could this be the breakthrough we've been waiting for in the fight against chronic hepatitis B? What are your thoughts on this groundbreaking development? Feel free to share your insights and opinions in the comments below!
